Mesothelioma Cancer Centers
University of California San Francisco at Mount Zion
Doctors Affiliated with this Treatment Facility
Headquartered at the medical center’s Mount Zion campus in San Francisco, California, the Helen Diller Family Comprehensive Cancer Center is the renowned cancer treatment arm of the University of California San Francisco Medical Center (UCSF). Named after a Bay Area philanthropist, the Helen Diller Cancer Center brings together scientists and clinicians from a wide spectrum of backgrounds with one shared goal: preventing and eradicating cancer. Its success has been notable.
A key figure in the history of UCSF’s cancer care was David A. Wood, a respected doctor who served as the first director of the UCSF Cancer Research Institute starting in 1948. Wood brought to his position a belief that to cure cancer, the medical community must take a “multidisciplinary approach, both clinical and basic scientists working together.” This philosophy remains central to the hospital’s beliefs today.
In 1999, UCSF’s cancer center was designated a “comprehensive cancer center” by the National Institutes of Health, the highest possible designation bestowed by the government agency. The title recognized the center for its scientific excellence, diverse research tactics, excellent patient care, and effective outreach activities that seek to prevent as well as control cancer. In 2007, the UCSF cancer center was renamed as the UCFS Helen Diller Family Comprehensive Cancer Center, paying tribute to support from Bay Area resident Helen Diller and her family.
The University of California San Francisco at Mount Zion fully understands diagnosing and treating mesothelioma. They take a careful approach to develop treatment plans unique to the patient's situation and type of mesothelioma. Patients seeking treatment at this cancer center can also undergo clinical trials.
- Clinical trials
- Standard and experimental mesothelioma treatments
Mesothelioma Clinical Trials at University of California San Francisco at Mount Zion
The following clinical trials are in progress or actively recruiting participants at University of California San Francisco at Mount Zion:
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
Conditions: Advanced Solid Tumors or Lymphomas Last Updated: May 3, 2019 Status: Active, not recruiting
Conditions: Melanoma; Breast Carcinoma; Hepatocellular Carcinoma; Urothelial Carcinoma; Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Colorectal Carcinoma; Non-small Cell Lung Carcinoma; Gastric or Gastroesophageal Junction Adenocarcinoma; Endometrial Carcinoma; Mesothelioma; Neuroendocrine Carcinoma; Cervical Cancer; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of the Anus Last Updated: April 29, 2019 Status: Recruiting
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Conditions: Mesothelioma Last Updated: April 26, 2019 Status: Active, not recruiting
Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Conditions: Mesothelioma Last Updated: March 15, 2019 Status: Recruiting
Conditions: Mesothelioma; BAP1 Loss of Function Last Updated: March 13, 2019 Status: Active, not recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
UCSF. Thoracic Oncology Program. About the Thoracic Oncology Program.